Is IMMPF or DIVO a better dividend investment in 2026?

IMMPF currently yields 3529.41% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: IMMPF offers higher current income.

What is the dividend yield difference between IMMPF and DIVO?

IMMPF has a forward dividend yield of 3529.41% ($3.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 3522.92 percentage points.

Home › Compare › IMMPF vs DIVO

IMMPF vs DIVO: Dividend Comparison 2026

IMMPF yields 3529.41% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IMMPF wins by $2151927237632.55M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IMMPF

● Live price

3529.41%

Share price

$0.09

Annual div

$3.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2151927237632.58M

Annual income

$2,038,319,550,631,819,300.00

Full IMMPF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — IMMPF vs DIVO

📍 IMMPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IMMPF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IMMPF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IMMPF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMMPF

Annual income on $10K today (after 15% tax)

$300,000.00/yr

After 10yr DRIP, annual income (after tax)

$1,732,571,618,037,046,300.00/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, IMMPF beats the other by $1,732,571,618,037,045,500.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMMPF + DIVO for your $10,000?

IMMPF: 50%DIVO: 50%

100% DIVO50/50100% IMMPF

Portfolio after 10yr

$1075963618816.31M

Annual income

$1,019,159,775,315,910,100.00/yr

Blended yield

94.72%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMMPF buys

DIVO buys

No recent congressional trades found for IMMPF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIMMPFDIVO

Forward yield	3529.41% ✓	6.49%
Annual dividend / share	$3.00 ✓	$2.91
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2151927237632.58M ✓	$30.7K
Annual income after 10y	$2,038,319,550,631,819,300.00 ✓	$981.68
Total dividends collected	$2144135504039.73M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: IMMPF vs DIVO ($10,000, DRIP)

Year	IMMPF Portfolio	IMMPF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$363,641	$352,941.18	$11,349	$649.42	+$352.3K → IMMPF
2	$12,383,857	$11,994,761.18	$12,833	$688.83	+$12.37M → IMMPF
3	$395,010,981	$381,760,253.60	$14,459	$727.90	+$395.00M → IMMPF
4	$11,803,130,868	$11,380,469,118.13	$16,238	$766.49	+$11803.11M → IMMPF
5	$330,437,068,596	$317,807,718,567.85	$18,179	$804.47	+$330437.05M → IMMPF
6	$8,668,758,125,687	$8,315,190,462,289.50	$20,293	$841.71	+$8668758.11M → IMMPF
7	$213,147,085,330,887	$203,871,514,136,401.38	$22,591	$878.14	+$213147085.31M → IMMPF
8	$4,912,912,994,478,026	$4,684,845,613,173,977.00	$25,087	$913.65	+$4912912994.45M → IMMPF
9	$106,175,408,411,930,130	$100,918,591,507,838,660.00	$27,791	$948.18	+$106175408411.90M → IMMPF
10	$2,151,927,237,632,584,700	$2,038,319,550,631,819,300.00	$30,718	$981.68	+$2151927237632.55M → IMMPF

IMMPF vs DIVO: Complete Analysis 2026

IMMPF — Stock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Full IMMPF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this IMMPF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMMPF vs SCHD IMMPF vs JEPI IMMPF vs O IMMPF vs KO IMMPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.